Key result
Patients with a history of cancer were significantly less likely to be prescribed statins at the time of cardiology admission compared to those without a history of cancer (OR 0.38).
Cross-Sectional (n=320)
No
Odds Ratio: 0.38 (95% CI 0.2–0.7)
Absolute Event Rate: 63.8% vs 79.7%
p-value: p=0.002
Highlights the inconsistent use of cardioprotective medications in cancer patients and survivors despite their increased risk of cardiovascular disease.
Modern cancer therapies have led to improved survival rates for many cancers. Rates of cardiovascular diseases (CVD) and risk factors are increased in cancer patients and survivors compared with the general population, and CVD has emerged as a leading cause of long-term morbidity and mortality in this population (1). Cardioprotective medications, including statins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and antiplatelet therapies remain cornerstones of primary and secondary CVD prevention. However, data regarding the use of cardioprotective medications among cancer patients and survivors have been inconsistent.
No takes yet. Share an insight, caveat, or question.
Untaru et al. (2020) conducted a cross-sectional in Cardiovascular Disease (n=320). History of cancer vs. No history of cancer was evaluated on Prescription of statins at the time of admission (OR 0.38, 95% CI 0.20 to 0.70, p=0.002). Patients with a history of cancer were significantly less likely to be prescribed statins at the time of cardiology admission compared to those without a history of cancer (OR 0.38).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: